Summary
For Year 2026-27, Medicamen Biotech reports the following shareholding: Total Promoters at 40.46%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0.1%, Domestic Institutional Investors at 0.05%, and Retail at 59.39%. This breakdown provides a quick snapshot of ownership distribution for Medicamen Biotech in 2026-27.
Medicamen Biotech FAQs
As of 04-2026, the promoter shareholding in Medicamen Biotech stands at 40.46% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Medicamen Biotech is 0.1% and 0.05% respectively.
The retail shareholding of the Medicamen Biotech is 59.39%.
Changes in shareholding patterns of Medicamen Biotech can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Medicamen Biotech are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Medicamen Biotech Associated Pages
